---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022959"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T14:36:54.274736+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma FY2023 revenue $34.2M (+5.9% YoY); operating profit down $1.4M

## Summary
- FY2023 revenues $34.2M, up 5.9% from prior year; net income $3.6M.
- Operating profit $3.7M, a decrease of $1.4M due to higher R&D and sales-distribution investment.
- Company will host conference call June 30 at 11:30 AM EDT to discuss results.
- Stockholder questions accepted via email prior to the call.

## SEC filing metadata
- accession: 0001493152-23-022959
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315223022959/0001493152-23-022959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315223022959/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022959
- JSON: https://secwatch.observer/filing/0001493152-23-022959.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022959.txt

## Key facts
- Earnings Releases
  ELITE PHARMACEUTICALS INC /NV/ reported the fiscal year ended March 31, 2023 results: revenue $34.2 million, net income $3.6 million.
  - Period: the fiscal year ended March 31, 2023
  - Revenue: $34.2 million
  - Net income: $3.6 million
  - Result: reported results
  source text: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). Consolidated revenues for Fiscal 2023 were $34.2 million, an increase of $1.9 million or 5.9% as compared to the comparable period of the prior fiscal year. Operating profits were $3.7 million, a decrease of $1.4 million from the comparable period of the prior year, and net income was $3.6 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053369/000149315223022959/0001493152-23-022959-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.